Case number 1:21-cv-00282
Vanda Pharmaceuticals Inc. v. Apotex Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 26, 2021 | 21 | SO ORDERED (5) Docket Text: SO ORDERED, re (21 in 1:21-cv-00121-CFC, 23 in 1:21-cv-00283-CFC, 227 in 1:18-cv-00651-CFC, 20 in 1:21-cv-00282-CFC) Stipulation and Order for Consolidation filed by Vanda Pharmaceuticals Inc. ALL FUTURE FILINGS SHALL BE MADE IN THE LEAD CONSOLIDATED ACTION, C.A. NO. 18-651-CFC. Signed by Judge Colm F. Connolly on 4/26/2021. Associated Cases: 1:18-cv-00651-CFC, 1:21-cv-00121-CFC, 1:21-cv-00282-CFC, 1:21-cv-00283-CFC(fms) |
| Apr 26, 2021 | N/A | Remark (0) Docket Text: Remark: ALL FUTURE FILINGS SHALL BE MADE IN THE LEAD CONSOLIDATED ACTION, C.A. NO. 18-651-CFC. Associated Cases: 1:21-cv-00121-CFC, 1:21-cv-00282-CFC, 1:21-cv-00283-CFC(fms) |
| Apr 26, 2021 | N/A | Create Case Association (0) Docket Text: Case associated with lead case: Create association to 1:18-cv-00651-CFC. (fms) |
| Apr 21, 2021 | 20 | Stipulation (5) Docket Text: Proposed STIPULATION and Order for Consolidation by Vanda Pharmaceuticals Inc.. (Fahnestock, Derek) |
| Apr 20, 2021 | 19 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of Vanda Pharmaceuticals Inc.'s Intrinsic Evidence Supporting Claim Construction for Wave 3 Patents filed by Vanda Pharmaceuticals Inc..(Jacobs, Karen) |
| Apr 16, 2021 | 18 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Apotex Inc. and Apotex Corp.'s Objections and Responses to Vanda's First Interrogatory to Apotex (No. 1) Regarding U.S. Patent Nos. 10,610,510; 10,610,511; 10,829,465; and 10,611,744 filed by Apotex Corp., Apotex Inc..(Francella, Thomas) |
| Apr 16, 2021 | 17 | Order (2) Docket Text: ORDER: IT IS ORDERED that, on or before May 17, 2021, counsel for the parties shall confer regarding coordination of the cases and submit a proposed scheduling order to the Court or otherwise advise the Court that a separate scheduling conference is needed. ORDER, Setting Deadlines: ( Notice of Compliance deadline set for 5/17/2021.) Signed by Judge Colm F. Connolly on 4/16/2021. Associated Cases: 1:21-cv-00121-CFC, 1:21-cv-00282-CFC, 1:21-cv-00283-CFC(nmf) |
| Apr 12, 2021 | 16 | Notice of Service (5) Docket Text: NOTICE OF SERVICE of Plaintiff Vanda Pharmaceuticals Inc.'s Proposed Claims and Constructions for Wave 3 Patents filed by Vanda Pharmaceuticals Inc..(Jacobs, Karen) |
| Mar 26, 2021 | N/A | Add Corporate Affiliates/Parents (0) Docket Text: Corporate Affiliates/Parents added per Disclosure Statement: identifying Corporate Parent Apotex Pharmaceutical Holdings, Inc. for Apotex Corp., Apotex Inc. (fms) |
| Mar 26, 2021 | 14 | Answer to Amended Complaint (27) Docket Text: ANSWER to Amended Complaint, re: [10] Amended Complaint by Apotex Corp., Apotex Inc..(Francella, Thomas) |
| Mar 26, 2021 | 15 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Apotex Holdings, Inc. for Apotex Corp., Apotex Inc. filed by Apotex Corp., Apotex Inc.. (Francella, Thomas) |
| Mar 17, 2021 | 13 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Vanda's First Interrogatory to Apotex (No. 1) Regarding U.S. Patent Nos. 10,610,510; 10,610,511; 10,829,465; and 10,611,744 filed by Vanda Pharmaceuticals Inc..(Fahnestock, Derek) |
| Mar 15, 2021 | 12 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Vanda's Disclosure of Asserted Claims and Contentions Regarding Infringement by Apotex of U.S. Patent Nos. 10,610,510 and 10,610,511, (2) Vanda's Disclosure of Asserted Claims and Contentions Regarding Infringement by Apotex of U.S. Patent Nos. 10,829,465 and 10,611,744, and (3) Disclosure of Accused Products and the Asserted Patents and Claims for U.S. Patent Nos. 10,610,510, 10,610,511, 10,829,465 and 10,611,744 filed by Vanda Pharmaceuticals Inc..(Fahnestock, Derek) |
| Mar 12, 2021 | 11 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,829,465 B2 ;10,611,744 B2 (Amended). (Fahnestock, Derek) |
| Mar 12, 2021 | 10 | Amended Complaint* (1) |
| Mar 12, 2021 | 10 | Main Document (23) Docket Text: First AMENDED COMPLAINT for Patent Infringement against Apotex Corp., Apotex Inc.- filed by Vanda Pharmaceuticals Inc.. (Attachments: # (1) Exhibits A-B)(Fahnestock, Derek) |
| Mar 12, 2021 | 10 | Exhibits A-B (22) |
| Mar 4, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (7 in 1:21-cv-00283-CFC, 9 in 1:21-cv-00282-CFC) MOTION for Pro Hac Vice Appearance of Attorney Nicholas Groombridge, Eric Alan Stone, Josephine Young, Daniel J. Klein, Jennifer Rea Deneault & Michael F. Milea filed by Vanda Pharmaceuticals Inc. Signed by Judge Colm F. Connolly on 3/4/2021. Associated Cases: 1:21-cv-00282-CFC, 1:21-cv-00283-CFC(nmf) |
| Mar 3, 2021 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:21-cv-00282-CFC, 1:21-cv-00283-CFC (rjb) |
| Mar 1, 2021 | 9 | Motion for Leave to Appear Pro Hac Vice (10) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Nicholas Groombridge, Eric Alan Stone, Josephine Young, Daniel J. Klein, Jennifer Rea Deneault & Michael F. Milea - filed by Vanda Pharmaceuticals Inc.. (Fahnestock, Derek) |
| Feb 25, 2021 | 6 | Summons Issued - Electronic (2) Docket Text: Summonses Issued (please complete the top portion of the form and print out for use/service). (amf) |
| Feb 25, 2021 | 7 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Vanda Pharmaceuticals Inc.. Apotex Inc. served on 2/25/2021, answer due 3/18/2021. (Fahnestock, Derek) |
| Feb 25, 2021 | 8 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Vanda Pharmaceuticals Inc.. Apotex Corp. served on 2/25/2021, answer due 3/18/2021. (Fahnestock, Derek) |
| Feb 24, 2021 | 1 | Main Document (12) Docket Text: COMPLAINT FOR PATENT INFRINGEMENT - filed against Apotex Corp., Apotex Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3544059.) - filed by Vanda Pharmaceuticals Inc. (Attachments: # (1) Exhibit A, # (2) Civil Cover Sheet)(amf) |
| Feb 24, 2021 | 5 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Blackrock for Vanda Pharmaceuticals Inc. - filed by Vanda Pharmaceuticals Inc.. (amf) |
| Feb 24, 2021 | 4 | ANDA Form (1) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 12/18/2020. Date of Expiration of Patent: 2/12/2035.Thirty Month Stay Deadline: 7/31/2021. (amf) |
| Feb 24, 2021 | 3 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,829,465 B2. (amf) |
| Feb 24, 2021 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (amf) |
| Feb 24, 2021 | 1 | Civil Cover Sheet (1) |
| Feb 24, 2021 | 1 | Exhibit A (11) |
| Feb 24, 2021 | 1 | Complaint* (1) |
